Catheter Precision reports nine-month revenue of $314K; cash at $5.6M

Catheter Precision, Inc.

Nine-month revenue $314K; total assets $32.9M; cash $5.6M as of Sep 30, 2023.
Received first approval in France; VIVO now active in six European countries.
Completed enrollment of Phase I LockeT study (>100 patients); IRB approval for Phase II randomized study.
Initiated design changes to LockeT based on feedback; new build processes for VIVO to reduce costs.
Acting CEO David Jenkins expects hospital approvals and purchase orders in coming months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Catheter Precision, Inc. reported three and nine months ended September 30, 2023 results: revenue $314 thousand.

Period: three and nine months ended September 30, 2023
Revenue: $314 thousand
Result: reported results

Exact text from the filing

assets at September 30, 2023, were $32.9 million. · Total cash on hand at September 30, 2023 was $5.6 million. · Total revenues for the nine months ended September 30, 2023 were $314 thousand. David Jenkins, acting CEO, commented: “We are pleased to have the Q3 financial filings completed and have a lot of momentum as we move into the fourth quarter. Our sales and

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-015944

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.